Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

• Guillaume Cartron,
• Rémi Letestu,
• Caroline Dartigeas,
• Mira Tout,
• Béatrice Mahé,
• Anne-Laure Gagez,
• Emmanuelle Ferrant,
• Boris Guiu,
• Bruno Villemagne,
• Phan Letuan,
• Thérèse Aurran,
• Frédérique Orsini-Piocelle,
• Anne Banos,
• Pierre Feugier,
• Véronique Leblond,
• Sophie de Guibert,
• Olivier Tournilhac,
• Jehan Dupuis,
• Alain Delmer,
• Valérie Rouillé,
• David Ternant,
• Stéphane Leprêtre

Affiliations

Guillaume Cartron

Department of clinical hematology, University hospital of Montpellier, France;CNRS UMR 5235, University of Montpellier, France

Rémi Letestu

APHP, HUPSSD, Hospital Avicenne, Department of biological hematology, Bobigny, France

Caroline Dartigeas

Department of clinical hematology, University hospital of Tours, France

Mira Tout

CNRS UMR 7292, François Rabelais University, University hospital of Tours, France

Béatrice Mahé

Department of clinical hematology, University hospital of Nantes, France

Anne-Laure Gagez

Department of clinical hematology, University hospital of Montpellier, France

Emmanuelle Ferrant

Department of clinical hematology, University hospital of Dijon, France

Boris Guiu

Department of Radiology, University hospital of Montpellier, France

Bruno Villemagne

Department of hematology-oncology, Departmental Hospital La Roche-sur-Yon, France

Phan Letuan

Laboratory of Biostatistics, University institute of Clinical Research, Montpellier, France

Thérèse Aurran

Paoli Calmette Center, Marseille, France

Frédérique Orsini-Piocelle

Department of clinical hematology, Hospital of Annecy, France

Anne Banos

Department of clinical hematology, Hospital Côte Basque, Bayonne, France

Pierre Feugier

Department of clinical hematology, University hospital of Nancy, France

Véronique Leblond

Department of clinical hematology, UPMC University of Paris 6, GRC11, Hospital La Pitié Salpêtrière, France

Sophie de Guibert

Department of clinical hematology, University hospital of Rennes, France

Olivier Tournilhac

Department of clinical hematology, University hospital of Clermont-Ferrand, France

Jehan Dupuis

Fonctional unit Lymphoid malignancies, University hospital Henri Mondor, Créteil, France

Alain Delmer

Department of clinical hematology, University hospital of Reims, Rouen, France

Valérie Rouillé

Department of clinical hematology, University hospital of Montpellier, France

David Ternant

CNRS UMR 7292, François Rabelais University, University hospital of Tours, France;Laboratory of Pharmacology-Toxicology, CNRS, UMR7292, University hospital of Tours, Rouen, France

Stéphane Leprêtre

Inserm U1245 and department of hematology, Henri Becquerel Center and university of Normandy UNIROUEN, Rouen, France